Navigation Links
ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Date:1/5/2012

es, and the development, activity, therapeutic potential and safety of ISIS-TTRRx. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of mipomersen, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2010 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. 


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
2. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
3. Cardium Reports on Renewed Compliance With NYSE Amex Exchange Listing Guidelines
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. Solos Endoscopy, Inc. Reports Significant Sales From Its MammoView® Instrument Line
6. VIVUS Reports Topline Findings From FORTRESS
7. Angeion Corporation Reports Fourth Quarter and Fiscal Year 2011 Operating Results
8. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
9. American Pacific Reports Fiscal 2011 Results
10. Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
11. Cantel Medical Reports 25% Increase in Net Income - EPS of $0.35 vs. $0.29 - for Quarter Ended October 31, 2011 on 30% Sales Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... YORK, April 20, 2011 Reportlinker.com announces that a ... Successful Strategies for Drug Repositioning ... Introduction This report Highlights ... to drug development. The success of the approach is ...
... Sagent Pharmaceuticals (Nasdaq: SGNT ) announced the ... of the offering has been increased from the previously announced ... stock at a price to the public of $16.00 per ... NASDAQ Global Market on April 20, 2011 under the ticker ...
Cached Medicine Technology:Reportlinker Adds Successful Strategies for Drug Repositioning 2Reportlinker Adds Successful Strategies for Drug Repositioning 3Reportlinker Adds Successful Strategies for Drug Repositioning 4Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering 2
(Date:4/18/2014)... University School of Medicine researchers have been awarded two-year ... Novo Nordisk announced this month. Of the 110 initial ... Biologics Science Forum Program, only four projects were funded, ... They are Jonathan Powell, M.D., Ph.D.; G. William Wong, ... Powell, a professor of oncology, will use his $500,000 ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at ... how blocking a particular molecule in metastatic breast cancer ... number of lung metastases. BRI scientists have found in ... shrink tumors by 60 - 80 percent and can ... lung. The $1.8 million five-year grant comes from the ...
(Date:4/18/2014)... Diego, Calif. (April 18, 2014) ― A new study ... analyzing weekly patterns in health-related Google searches reveals a ... health strategies. , Investigators from San Diego ... and the Monday Campaigns, analyzed "healthy" Google searches (searches ... e.g., "healthy diet") originating in the U.S. from 2005 ...
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... ... Hospital Association’s (MHA) Quality Indicator Project® has signed an agreement with ... solution with 3M™ ClinTrac™ Quality Manager Software. The joint solution ... analytical tools, and comparative reports in an integrated system, allowing hospitals ...
... new national survey on public attitudes toward medical applications ... support for the technology increases when the public is ... benefits at least among those people who have ... researchers at North Carolina State University and Arizona State ...
... researchers at Columbia University,s Mailman School of Public Health ... genes, altering their functions and leading to the development ... suggest a new biological model of PTSD in which ... a person,s stress response and leads to the disorder," ...
... NY MAY 4, 2010 TCT for Surgeons ... techniques in the field that are improving outcomes for ... the course will run during Transcatheter Cardiovascular Therapeutics (TCT) ... Cardiovascular Research Foundation. "This meeting will drive forward ...
... ... County, Maryland offer convenient access to the Baltimore/Washington metropolitan areas—without the high costs. ... Hagerstown, MD (PRWEB) ... the nation’s leading biotech convention, but the Hagerstown-Washington County Economic Development Commission will be ...
... ... websites to businesses looking to grow through seo services. The Atlanta SEO Company offers this ... ... put a strain on many marketing budgets in the Atlanta metro area. We all know ...
Cached Medicine News:Health News:3M and Maryland Hospital Association's Quality Indicator Project Partner to Deliver Comprehensive Quality Solution 2Health News:3M and Maryland Hospital Association's Quality Indicator Project Partner to Deliver Comprehensive Quality Solution 3Health News:Survey: Hiding risks can hurt public support for nanotechnology 2Health News:Trauma-induced changes to genes may lead to PTSD 2Health News:Western Maryland to be Featured at BIO International Convention 2Health News:Western Maryland to be Featured at BIO International Convention 3Health News:Western Maryland to be Featured at BIO International Convention 4Health News:Atlanta SEO Company Offers Free Websites to Help Businesses Grow Again in the Tough Economy 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: